AstraZeneca PLC has signed an exclusive framework agreement with Shenzhen Kangtai Biological Products of China for its candidate Vaccine Covid-19 to mainland China, the British pharmaceutical giant announced Thursday.
To meet the demand of the Chinese market, Shenzhen Kangtai is required to ensure that it has an annual production capacity of at least one hundred million doses of azD1222 experimental cooking, AstraZeneca has jointly developed with researchers from the University of Oxford to the end. this year, and has a capacity of at least two hundred million doses through the end of next year, AstraZeneca said on a Chinese weChat social networking site.
The two corporations will also explore cooperation on the candidate vaccine in other markets, AstraZeneca said.
“O item.title”